A novel antibody targeting the ligand binding domain of the thromboxane A 2 receptor exhibits antithrombotic properties in vivo

Biochemical and Biophysical Research Communications

Volumn 421, Issue 3, 2012, Pages 456-461

  Murad, John P ^a   Espinosa, Enma Veronica Paez ^a   Ting, Harold J ^a   McClure, Diane ^a   Khasawneh, Fadi T ^a  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

Antibody therapy; Antithrombotic agents; Hemostasis; Platelets; Thrombosis; Thromboxane A 2 receptor

Indexed keywords

ANTIBODY; ANTICOAGULANT AGENT; C TERMINUS OF THE SECOND EXTRACELLULAR LOOP ANTIBODY; THROMBOXANE A2 RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BINDING SITE; BLEEDING TIME; CAROTID ARTERY THROMBOSIS; CONTROLLED STUDY; HEMOSTASIS; IN VIVO STUDY; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION;

ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE MODELS, ANIMAL; FIBRINOLYTIC AGENTS; LIGANDS; MICE; MICE, INBRED C57BL; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; THROMBOSIS;

MUS; ORYCTOLAGUS CUNICULUS;

EID: 84860680009     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.04.011     Document Type: Article

References (32)

1. Bembenek J.P., Karlinski M., Kobayashi A., Czlonkowska A. Deep venous thrombosis in acute stroke patients. Clin. Appl. Thromb. Hemost. 2011.
2. Ergelen M., Gorgulu S., Uyarel H., Norgaz T., Aksu H., Ayhan E., Gunaydin Z.Y., Isik T., Tezel T. The outcome of primary percutaneous coronary intervention for stent thrombosis causing ST-elevation myocardial infarction. Am. Heart J. 2010, 159:672-676.
3. Breet N.J., Sluman M.A., van Berkel M.A., van Werkum J.W., Bouman H.J., Harmsze A.M., Kelder J.C., Zijlstra F., Hackeng C.M., Ten Berg J.M. Effect of gender difference on platelet reactivity. Neth. Heart J. 2011, 19:451-457.
4. Ogletree M.L. Overview of physiological and pathophysiological effects of thromboxane A2. Fed. Proc. 1987, 46:133-138.
5. Patrono C., Ciabattoni G., Davi G. Thromboxane biosynthesis in cardiovascular diseases. Stroke 1990, 21:130-133. IV.
6. Okuma M., Hirata T., Ushikubi F., Kakizuka A., Narumiya S. Molecular characterization of a dominantly inherited bleeding disorder with impaired platelet responses to thromboxane A2. Pol. J. Pharmacol. 1996, 48:77-82.
7. Fields W.S., Lemak N.A., Frankowski R.F., Hardy R.J. Controlled trial of aspirin in cerebral ischemia. Stroke 1977, 8:301-314.
8. Clarke R.J., Mayo G., Price P., FitzGerald G.A. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N. Engl. J. Med. 1991, 325:1137-1141.
9. Patrono C. Aspirin as an antiplatelet drug. N. Engl. J. Med. 1994, 330:1287-1294.
10. Aradi D., Magyarlaki T., Tokes-Fuzesi M., Rideg O., Vorobcsuk A., Komocsi A. Comparison of conventional aggregometry with VASP for monitoring P2Y12-specific platelet inhibition. Platelets 2010, 21:563-570.
11. Lippi G., Montagnana M., Danese E., Favaloro E.J., Franchini M. Glycoprotein IIb/IIIa inhibitors: an update on the mechanism of action and use of functional testing methods to assess antiplatelet efficacy. Biomark. Med. 2011, 5:63-70.
12. Mazzaferri E.L., Young J.J. Abciximab: a review and update for clinicians. Expert Rev. Cardiovasc. Ther. 2008, 6:609-618.
13. Schror K., Weber A.A. Comparative pharmacology of GP IIb/IIIa antagonists. J. Thromb. Thrombolysis 2003, 15:71-80.
14. Younis N., Williams S., Soran H. Aspirin therapy and primary prevention of cardiovascular disease in diabetes mellitus. Diabetes Obes. Metab. 2009, 11:997-1000.
15. Moberg C., Naesdal J., Svedberg L.E., Duchateau D., Harte N. Impact of gastrointestinal problems on adherence to low-dose acetylsalicylic Acid: a quantitative study in patients with cardiovascular risk. Patient 2011, 4:103-113.
16. Murad J.P., Espinosa E.V., Ting H.J., Khasawneh F.T. The C-terminal segment of the second extracellular loop of the thromboxane A(2) receptor plays an important role in platelet aggregation. Biochem. Pharmacol. 2012, 83:88-96.
17. Turek J.W., Halmos T., Sullivan N.L., Antonakis K., Le Breton G.C. Mapping of a ligand-binding site for the human thromboxane A2 receptor protein. J. Biol. Chem. 2002, 277:16791-16797.
18. Offermanns S., Toombs C.F., Hu Y.H., Simon M.I. Defective platelet activation in G alpha(q)-deficient mice. Nature 1997, 389:183-186.
19. Kurz K.D., Main B.W., Sandusky G.E. Rat model of arterial thrombosis induced by ferric chloride. Thromb. Res. 1990, 60:269-280.
20. Matsuno H., Uematsu T., Niwa M., Kozawa O., Nagashima S., Kohno K., Kato H., Kawabata Y., Yoshida Y., Kanamaru M. Pharmacokinetic and pharmacodynamic properties of a new thromboxane receptor antagonist (Z-335) after single and multiple oral administrations to healthy volunteers. J. Clin. Pharmacol. 2002, 42:782-790.
21. Drouet L., Ripoll L. Targets of antithrombotic drugs. Med. Sci. (Paris) 2006, 22:887-894.
22. Feng J., Liu Y., Chu L.M., Clements R.T., Khabbaz K.R., Robich M.P., Bianchi C., Sellke F.W. Thromboxane-induced contractile response of human coronary arterioles is diminished after cardioplegic arrest. Ann. Thorac. Surg. 2011, 92:829-836.
23. Tarbell J.M. Shear stress and the endothelial transport barrier. Cardiovasc. Res. 2010, 87:320-330.
24. Roberts C.J., Williams P.M., Davies J., Dawkes A.C., Sefton J., Edwards J.C., Haymes A.G., Bestwick C., Davies M.C., Tendler S.J.B. Real-Space differentiation of IgG and IgM antibodies deposited on microtiter wells by scanning force microscopy. Langmuir 1995, 11:1822-1826.
25. Mumford A.D., Dawood B.B., Daly M.E., Murden S.L., Williams M.D., Protty M.B., Spalton J.C., Wheatley M., Mundell S.J., Watson S.P. A novel thromboxane A2 receptor D304N variant that abrogates ligand binding in a patient with a bleeding diathesis. Blood 2010, 115:363-369.
26. Hirata T., Kakizuka A., Ushikubi F., Fuse I., Okuma M., Narumiya S. Arg60 to Leu mutation of the human thromboxane A2 receptor in a dominantly inherited bleeding disorder. J. Clin. Invest. 1994, 94:1662-1667.
27. Moustapha A., Assali A.R., Sdringola S., Yusuf S.W., Vaughn W.K., Fish R.D., Schroth G.W., Krajcer Z., Rosales O.R., Smalling R.W., Anderson H.V. Abciximab administration and clinical outcomes after percutaneous intervention for in-stent restenosis. Catheter Cardiovasc. Interv. 2002, 56:184-187.
28. Lajus S., Clofent-Sanchez G., Jais C., Coste P., Nurden P., Nurden A. Thrombocytopenia after abciximab use results from different mechanisms. Thromb. Haemost. 2010, 103:651-661.
29. Watson T.D., Stark J.E., Vesta K.S. Pantoprazole-induced thrombocytopenia. Ann. Pharmacother. 2006, 40:758-761.
30. Eitel I., Desch S., Schindler K., Fuernau G., Schuler G., Thiele H. Aborted myocardial infarction in intracoronary compared with standard intravenous abciximab administration in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction. Int. J. Cardiol. 2011, 153:21-25.
31. Cao Y., Marks J.D., Huang Q., Rudnick S., Xiong C., Hittelman W.N., Wen X., Marks J.W., Cheung L.H., Boland K., Li C., Adams G.P., Rosenblum M.G. Single-chain antibody based immunotoxins targeting Her2/neu. Design optimization and impact of affinity on antitumor efficacy and off-target toxicity. Mol Cancer Ther. 2012, 11:143-153.
32. Ishihara H., Zeng D., Connolly A.J., Tam C., Coughlin S.R. Antibodies to protease-activated receptor 3 inhibit activation of mouse platelets by thrombin. Blood 1998, 91:4152-4157.